Shree Pacetronix Ltd (527005)
🎯 Key Takeaways
- Shree Pacetronix Ltd appears to be in a volatile turnaround or stabilization phase, marked by erratic financial performance and declining promoter stake. The company operates in the healthcare sector but shows no consistent growth trajectory, with revenue and profitability fluctuating significantly across quarters.
- Revenue declined 8.8% QoQ to ₹5 in Q1FY27.
- ⚠️ 1) Persistent revenue volatility with no clear growth trend, as seen in the sharp decline from ₹7 crore to ₹4 crore in consecutive quarters. 2) Declin
📖 The Story
Shree Pacetronix Ltd appears to be in a volatile turnaround or stabilization phase, marked by erratic financial performance and declining promoter stake. The company operates in the healthcare sector but shows no consistent growth trajectory, with revenue and profitability fluctuating significantly across quarters. Despite strong ROE and ROCE figures, these are not translating into sustainable operational momentum, suggesting potential structural or strategic challenges.
📰 What's Happening
Management has not announced any major new orders or expansions in recent filings, but there are signs of operational volatility — revenue dropped sharply from ₹7 crore in September 2025 to ₹4 crore in December 2025, with operating profit turning negative. The company reported a return to profitability in March 2026 with ₹1 crore revenue and ₹1 crore operating profit, though margins remain inconsistent. There has been a significant decline in promoter holding from 36.44% in Q1FY27 to 31.7% in Q4FY26, accompanied by a drop in institutional and retail investor presence, raising governance and confidence concerns.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 5 | 7 | 4 | 5 | 5 |
| Operating Profit | 1 | 2 | 0 | 1 | 1 |
| OPM % | 18.5% | 27.6% | 6.2% | 26.4% | 20.6% |
| Net Profit | 1 | 1 | 0 | 1 | 1 |
| EPS | ₹1.85 | ₹3.64 | ₹0.16 | ₹3.06 | ₹2.02 |
The financial trajectory reflects high volatility, with revenue peaking at ₹7 crore in September 2025 before collapsing to ₹4 crore in December 2025, followed by a partial recovery to ₹5 crore in June 2026. Operating margins swung from a low of 6.2% in December 2025 to over 26% in September 2025 and March 2026, indicating operational instability rather than sustained improvement. While profitability and EPS improved in the latest quarter, these gains are from a very low base and do not yet signal a clear upward trend.
🔮 Management Outlook & What's Next
There is no explicit forward guidance or strategic outlook disclosed in the latest regulatory filings. Management commentary focuses on operational performance without articulating a multi-year growth plan, capital allocation strategy, or market expansion vision. The absence of guidance suggests either uncertainty or a lack of a defined roadmap, which may concern institutional investors.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 |
| Reserves | 10 | 10 | 12 | 14 |
| Borrowings | 6 | 5 | 5 | 3 |
| Total Liabilities | 25 | 23 | 25 | 26 |
| Fixed Assets | 4 | 4 | 4 | 4 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 25 | 23 | 25 | 26 |
The balance sheet shows minimal capital intensity and stable asset base, with total assets growing slowly from ₹23 crore to ₹26 crore over three years. Equity remains flat at ₹4 crore, while reserves have increased modestly, indicating retained earnings are limited. Borrowings have slightly increased but remain low at ₹3–5 crore, suggesting conservative leverage. There is no evidence of aggressive reinvestment or debt-funded expansion, implying capital allocation is defensive rather than growth-oriented.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -0 |
| Investing | -0 |
| Financing | +0 |
| Net Cash Flow | +0 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 25.8% | 31.7% | 36.4% |
| FII | 0.1% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% |
| Public | 45.9% | 45.8% | 45.8% |
| # Shareholders | 6,528 | 6,567 | 6,615 |
Promoter holding has declined sharply from 36.44% to 31.7% in one quarter, with no FII or DII presence in recent quarters — FII and DII holdings dropped to zero from 0.14% and 0% previously. The number of public shareholders has marginally increased, but overall shareholder base appears to be contracting. This trend signals eroding confidence among key investor groups, particularly institutions, and may reflect concerns over performance or governance.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 60.9 | 22.1% | 22.9% | 0.60 |
| MAXHEALTH | 1.01 L Cr | 69.2 | 14.4% | 13.6% | 0.27 |
| MANIPALHOS | 94,201 | — | — | — | 1.25 |
| FORTIS | 66,987 | 63.9 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 66,504 | 123.5 | 12.9% | 8.6% | 0.17 |
| MEDANTA | 38,921 | 69.9 | 21.9% | 16.3% | 0.10 |
| NH | 38,161 | 46.5 | 13.7% | 18.0% | 1.07 |
| KIMS | 32,292 | 150.8 | 9.7% | 8.7% | 1.44 |
| LALPATHLAB | 32,009 | 46.0 | 29.6% | 21.8% | 0.00 |
| POLYMED | 17,610 | 55.9 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent revenue volatility with no clear growth trend, as seen in the sharp decline from ₹7 crore to ₹4 crore in consecutive quarters. 2) Declining promoter stake combined with zero institutional holdings raises concerns about ownership stability and governance. 3) Inconsistent profitability and margins, with operating losses in key quarters despite high reported margins in others, suggest execution or demand issues. 4) Lack of forward guidance or strategic clarity from management leaves investors without visibility into recovery pathways.
📋 Recent Filings
-
🔴 annual report 5 September 2026Shree Pacetronix informed shareholders that the 38th Annual General Meeting is set for 29 September 2026 at its Pithampur registered office, and that ...
-
🟡 Board Meeting 5 September 2026Shree Pacetronix Limited announced its 38th Annual General Meeting scheduled for Tuesday, 29th September 2026 at 01:00 P.M. IST at its registered offi...
-
🔴 annual report 5 September 2026Shree Pacetronix Ltd's 38th Annual Report for FY 2025-26, filed with BSE on September 5, 2026, outlines governance details, including the upcoming AGM...
🧠 Analyst's Read
The company remains in a fragile state with no evident inflection point yet confirmed. Investors should monitor upcoming quarters for signs of stabilized revenue, margin improvement from a sustainable cost base, and any clarification from management on strategic direction. Until then, the investment profile remains speculative with elevated execution and confidence risks.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd